Alliance expands to include taxane purification
Novasep and instrAction have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds.
Novasep and instrAction have expanded their worldwide strategic alliance to include the purification of taxanes, a well-known class of anti-cancer compounds.
Novasep supplies manufacturing solutions to the life science industries, while instrAction manufactures stationary phases for API purification processes. The two companies announced a strategic alliance covering non-chiral chromatography in July 2010, and this extended collaboration will now allow Novasep to develop and operate or supply optimized large-scale chromatography processes for purification of taxane-based active pharmaceutical ingredients (APIs) and intermediates.
“Thanks to instrAction’s highly selective chromatographic stationary phases and Novasep’s 20 years’ experience in taxane synthesis and purification, we are looking to see a paradigm shift in solutions for our customers worldwide as a result of this collaboration,” says René De Vaumas, executive vice president in charge of Novasep Synthesis’ business development.
instrAction has synthesized a family of API-selective stationary phases among their 3000-phase library, which are reported to have shown a strong potential for the purification of various taxanes. Access to instrAction’s technology means Novasep expects to be able to develop a multi-step synthesis or semi-synthesis. The company can then scale up the optimized process and produce the API for clinical and commercial purposes. Alternatively, it can supply the developed process to its customers with performance guarantees, integrating its Prochrom HPLC columns and systems and instrAction’s selective stationary phases.
“We are delighted about our extended collaboration with Novasep,” said Dr Thomas Schwarz, CEO of instrAction. “The cooperation with Novasep in the field of taxane purification is a further important milestone to implement the instrAction technology in industrial downstream processes. We are very confident that it will be broadly applied to the industrial purification of APIs in the future.”
For more information on the companies visit www.novasep.com and www.instraction.com
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
